115 results about "Tissue transplantation" patented technology

Disclosed are conjugates which bind VLA-4. Certain of these conjugates also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such conjugates are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The conjugates can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

The present invention provides for the transplantation of tissue from a donor site in a body to a recipient site. The device includes an outer chamber having an interior volume in which a perforated inner chamber can be placed. During the aspiration of tissue, a vacuum is formed in the interior volume of the outer chamber, to draw tissue from a cannula into the perforated inner chamber. The perforations are sized such that fat is collected within the inner chamber, while fluids and other materials are drawn through the perforations, away from the collected fat. For reinjection, the inner chamber can be removed from the outer chamber, and a sleeve positioned to cover the perforations and thereby form a syringe body that can be interconnected to a needle and plunger for reinjection of the collected fat.

The present invention relates generally to improved methods for tissue engineering including tissue transplantation, augmentation and regeneration. More particularly, the present invention provides a method for the generation of donor vascularized tissue suitable for use in tissue transplantation, augmentation and / or repair. The present invention further enables the use of a support matrix in the generation of an anatomical construct comprising the donor vascular tissue. The support matrix may be devised such that it has dimensions of a size and shape adapted to simulate those of tissue to be transplanted, augmented and / or repaired. In addition to its use in tissue repair, the methods and support matrix of the present invention may also find application as a means for delivering a desirable gene product to a subject. The method and support matrix of the present invention is conveniently be made available in the form of a kit, for use generally in the field of tissue engineering.

A dermal tissue transplantation system combining a tissue particle harvester, a tissue particle collector, and a chambered dressing. The system provides a harvester capable of harvesting tissue from a donor site on the order of about 100 microns. The integrated tissue particle collector provides a means for collecting the harvested tissue for in situ cultivation in a chambered dressing at the wound site.

A dermal tissue transplantation system combining a tissue particle harvester, a tissue particle collector, and a chambered dressing. The system provides a harvester capable of harvesting tissue from a donor site on the order of about 100 microns. The integrated tissue particle collector provides a means for collecting the harvested tissue for in situ cultivation in a chambered dressing at the wound site.

Disclosed are compounds of the formula:and the pharmaceutically acceptable salts thereof wherein the variables A, n, R5, R21-R24 and Q are defined herein. These compounds bind VLA-4. Certain of these compound also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

A method of treating a subject in need of a non-syngeneic cell or tissue graft is disclosed. The methos comprising: (a) transplanting into a subject a dose of T cell depleted immature hematopoetic cells, wherein the T cell depleted immature hematopoetic cells comprise less than 5×105 CD3+ T cells per kilogram body weight of the subject, and wherein the dose comprises at least about 5×106 CD34+ cells per kilogram body weight of the subject, and wherein the T cell depleted immature hematopoetic cells are obtained by separating the T cells from the immature hematopoetic cells by magnetic cell sorting, and (b) administering to the subject a therapeutically effective amount of cyclophosphamide, wherein the therapeutically effective amount comprises 25-200 mg per body weight, thereby treating the subject.

System and methods for collecting and preparing fat for autologous fat tissue transplantation. The system includes syringes, filtering and transferring assemblies coupled with the syringes, a centrifuge and a centrifuge insert releasably coupled with the centrifuge. Substances, including oil, fat, and denser substances, such as tumescent fluid, connective tissue, hormones and / or other non-fat substances, are harvested through a cannula into a syringe. Syringes are placed in the centrifuge insert, and subject to centrifugation. Centrifugation stratifies the substances into a top oil stratum, a middle fat stratum, and a bottom denser substance stratum. Denser substances are filtered out of the syringes during or after centrifugation. Oil is removed through an aspiration port in the plunger head of the syringe plunger. Fat is transferred from the first syringe into one or more smaller syringes through an adapter in the assembly coupled with the first syringe and the smaller syringe.

The present invention provides compounds, pharmaceutical compositions and methods for treating, immuno-allergical diseases, autoimmune diseases, and organ or tissue rejection following transplantation.

The present invention provides a compound of formula (I) having an excellent JAK3 inhibition activity and being useful as an active ingredient of an agent for treating and / or preventing various immune diseases including autoimmune diseases inflammatory diseases, and allergic diseases. The compound according to the present invention has an inhibition activity against JAK3 and is thus useful as an active ingredient of an agent for treating or preventing diseases caused by undesirable cytokine signal transmission (e.g., rejection during organ / tissue transplantation, autoimmune diseases, multiple sclerosis, rheumatoid arthritis, psoriasis, asthma, atopic dermatitis, Alzheimer's disease, and atherosclerotic disease), or diseases caused by abnormal cytokine signal transmission (e.g., cancer and leukemia).

Provided are means and methods for producing embryoid bodies (EBs) from multi- or pluripotent cells. In particular, a method of generating embryoid bodies (EBs) is described comprising agitation of a liquid suspension culture of multi- or pluripotent cells in a container until generation of cell aggregates, optionally diluting the suspension, and further agitation of the suspension until formation of EBs. Furthermore, the present invention relates to the use of the novel culturing method and EBs obtained thereby for a variety of applications including genomics, diagnostic assays, teratogenic / embryotoxicological and pharmacological assays as well as for the provision of tissue grafts.

Scaleable, vascularised tissue constructs that are composed of a multiplicity of cell containing, discrete and separable modules, methods of fabricating same and uses thereof. The tissue construct is a tissue substitute used in tissue transplantation or substitution or for the purpose of in vitro mimic of normal tissue.

Methods and compositions for treating diseased or damaged tissue, such as Inflammatory Bowel Disease, e.g., Ulcerative Colitis, include tissue regeneration using stem cells or tissue grafts which stimulate stem cell migration to the damaged tissue. The tissue grafts can be extracellular matrix (ECM) material, such as tissue-specific extracellular matrix (TS-ECM). The methods can also include mucosal resection of the damaged or diseased tissue prior to placement of the graft.